Literature DB >> 28379808

177Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg1, Eric Krenning2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28379808     DOI： 10.1056/NEJMc1701616

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.

Authors:  Makoto Hosono
Journal:  Nucl Med Mol Imaging       Date:  2019-01-29

2.  The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges.

Authors:  Nitya Raj; Diane Reidy-Lagunes
Journal:  Pancreas       Date:  2018-01       Impact factor: 3.327

3.  ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs).

Authors:  Rohini Sharma; Susanna Slater; Joanne Evans; Maria Martinez; Caroline Ward; Hooshang Izadi; Florian Wernig; Rob Thomas
Journal:  BMC Cancer       Date:  2022-07-20       Impact factor: 4.638

4.  Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.

Authors:  Fabrice Viol; Bence Sipos; Martina Fahl; Till S Clauditz; Tania Amin; Malte Kriegs; Maike Nieser; Jakob R Izbicki; Samuel Huber; Ansgar W Lohse; Jörg Schrader
Journal:  Cell Oncol (Dordr)       Date:  2022-10-21       Impact factor: 7.051

5.  In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.

Authors:  Aleksandra Syguła; Aleksandra Ledwon; Kornelia Hasse-Lazar; Beata Jurecka-Lubieniecka; Barbara Michalik; Ewa Paliczka-Cieślik; Marcin Zeman; Ewa Chmielik; Joanna Sczasny; Barbara Jarzab; Daria Handkiewicz-Junak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-03       Impact factor: 10.057

Review 6.  From Initial Description by Wermer to Present-Day MEN1: What have We Learned?

Authors:  Nancy D Perrier
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

7.  Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE.

Authors:  Katherine I Wolf; Abhishek Jha; Anouk van Berkel; Damian Wild; Ingo Janssen; Corina M Millo; M J R Janssen; Melissa K Gonzales; Henri J K M Timmers; Karel Pacak
Journal:  Nucl Med Mol Imaging       Date:  2019-02-22

Review 8.  Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.

Authors:  Richard L Wahl; Panithaya Chareonthaitawee; Bonnie Clarke; Alexander Drzezga; Liza Lindenberg; Arman Rahmim; James Thackeray; Gary A Ulaner; Wolfgang Weber; Katherine Zukotynski; John Sunderland
Journal:  J Nucl Med       Date:  2021-01       Impact factor: 11.082

Review 9.  Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging.

Authors:  Rami Alrezk; Andres Suarez; Isabel Tena; Karel Pacak
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-27       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.